<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811508</url>
  </required_header>
  <id_info>
    <org_study_id>CHM-2020/S14/07</org_study_id>
    <nct_id>NCT04811508</nct_id>
  </id_info>
  <brief_title>Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use</brief_title>
  <acronym>CARMYN</acronym>
  <official_title>Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier le Mans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier le Mans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective multicenter observational study will provide real-life efficacy and&#xD;
      tolerance data for patients with relapsed multiple myeloma (RMM) treated with carfilzomib in&#xD;
      the context of nominative expanded access and compassionate use in France, and will allow to&#xD;
      evaluate healthcare practices from data obtained during the use of carfilzomib for routine&#xD;
      care. Nominative expanded access was open in February 2014 and stopped in march 2016, then&#xD;
      relayed by the compassionate program (march 2016- February 2017).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of carfilzomib treatment</measure>
    <time_frame>31 august 2021</time_frame>
    <description>Assess duration of carfilzomib treatment in adult patients with multiple myeloma who have received carfilzomib at first or second relapse according to the recommendations of the International Myeloma Working Group (time from the date of treatment initiation to the date of permanent discontinuation for any reason)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment</measure>
    <time_frame>31 august 2021</time_frame>
    <description>This is defined as the time from the date of treatment initiation (i.e. the date of the first day of the first cycle of the treatment with carfilzomib) to the date when the next line starts. Time to next treatment is censored at the date of death, if applicable. Patients still on carfilzomib treatment at the end of the study will be censored at the date of the last disease evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free survival (PFS)</measure>
    <time_frame>31 august 2021</time_frame>
    <description>Progression free survival is defined as the time from the date of initiation of treatment (i.e. the date of the first day of the first cycle of treatment with carfilzomib) to the date of the first disease progression, as defined by the investigator's judgement using IMWG criteria (1), or the date of death, whichever occurs first. Progression free survival is censored at the date of the last disease evaluation, if applicable</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Relapsed Multiple Myeloma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapsed multiple myeloma (RMM) treated with carfilzomib in the context of&#xD;
        nominative expanded access and compassionate use in France&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients over the age of 18 years&#xD;
&#xD;
          -  Patients beginning carfilzomib treatment in the framework of expanded access or&#xD;
             compassionate use in France (KRd or Kd regimen)&#xD;
&#xD;
          -  Patients who received carfilzomib in first or second MM relapse&#xD;
&#xD;
          -  Patients receiving at least one complete course of carfilzomib&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients already included in an interventional research protocol using carfilzomib at&#xD;
             the time of treatment initiation&#xD;
&#xD;
          -  Patients refusing to allow the computerization of their data&#xD;
&#xD;
          -  Patients for whom hospital medical records are not accessible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christelle JADEAU</last_name>
    <phone>02 44 71 07 81</phone>
    <email>cjadeau@ch-lemans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kamel LARIBI</last_name>
    <phone>02 43 43 43 43</phone>
    <email>klaribi@ch-lemans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle JADEAU</last_name>
      <phone>02 44 71 07 81</phone>
      <email>cjadeau@ch-lemans.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed multiple myeloma</keyword>
  <keyword>Carfilzomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

